

Contents

| | |
|--------------------------------------|-----|
| Welcome Message | iii |
| EULAR 2016 Abstracts Reviewers | iv |

Speakers Abstracts

Speaker Presentations

Wednesday, 8 June 2016

| | | |
|---------------|---|----|
| SP0001–SP0002 | WIN session 1 | 2 |
| SP0003–SP0005 | Catastrophizing pain in RA | 2 |
| SP0006 | Axial spondyloarthritis and psoriatic arthritis: emerging pathways | 3 |
| SP0007 | HOT session 1 | 3 |
| SP0008–SP0011 | Balancing benefits and risk of glucocorticoids; a challenge for implementation | 3 |
| SP0012–SP0013 | What CVD outcomes to use in clinical rheumatological practice? | 5 |
| SP0014–SP0017 | Different perspectives on pain in osteoarthritis | 5 |
| SP0018–SP0020 | Epigenetics solving the OA puzzle | 6 |
| SP0021–SP0022 | Muscle biology & inflammation | 7 |
| SP0023–SP0025 | Lessons from the children (monogenic causes of autoimmunity) | 7 |
| SP0026–SP0027 | ABC of statistics | 8 |
| SP0028–SP0031 | Capillaroscopy I | 8 |
| SP0032–SP0033 | Optimizing treatment and patient care through precision medicine: a threat or an opportunity for patients and patient organisations? | 9 |
| SP0034–SP0036 | EULAR projects in Musculoskeletal Imaging | 10 |
| SP0037 | Difficult osteoporosis | 10 |
| SP0038 | Clinical relevance of immunogenicity and therapeutic drug monitoring | 11 |
| SP0039–SP0040 | Hepatitis C and rheumatology: the impact of new therapies | 11 |
| SP0041–SP0043 | Outcome measures in clinical practice in gout and CPPD. The use of the new EULAR guidelines | 11 |
| SP0044–SP0045 | Hand osteoarthritis: state of the art and future perspectives | 12 |
| SP0046–SP0047 | Chronobiology of the immune response | 13 |
| SP0048–SP0050 | Nanomedicine in rheumatology | 13 |
| SP0051–SP0052 | HOT session 2 | 14 |
| SP0053–SP0056 | Beyond EMEUNET: development of a European-wide network of young clinicians from different specialties focusing on inflammatory diseases | 14 |
| SP0057 | Data visualisation: tables and graphs for publication and presentation I | 15 |
| SP0058–SP0060 | Ultrasound basic I | 16 |
| SP0061 | Patient organisations in action | 16 |
| SP0062–SP0063 | Hot topics in paediatric rheumatology | 16 |

Thursday, 9 June 2016

| | | |
|---------------|---|----|
| SP0064–SP0065 | Plasma cells as key players and therapeutic target in rheumatic diseases | 17 |
| SP0066–SP0068 | Global year against joint pain | 17 |
| SP0069–SP0070 | HOT session 4 | 18 |
| SP0071–SP0073 | Designing solutions to support young people to address the challenges of living with a rheumatic or musculoskeletal disease | 18 |
| SP0074 | WIN session 3 | 19 |
| SP0075–SP0076 | Advancements in the imaging of PsA | 19 |
| SP0077–SP0079 | When and how to treat Raynaud's phenomenon and related complications | 20 |
| SP0080–SP0081 | Role of new imaging techniques as RMD outcomes | 20 |
| SP0082–SP0085 | "Fewer words - more action" - tailored care for men with rheumatic diseases? | 20 |
| SP0086 | Recent advances in our understanding of macrophage biology | 21 |

| | | |
|-------------------------------|--|----|
| SP0087–SP0088 | Lubricants: potential as osteoarthritis treatment? | 21 |
| SP0089 | Extraarticular complications of JIA | 22 |
| SP0090 | The elephant in the room: how to avoid biases in research? | 22 |
| SP0091–SP0093 | Digital applications for the benefit of the patient | 23 |
| SP0094–SP0095 | EULAR projects in Clinical Affairs | 23 |
| SP0096–SP0097 | Optimization of MTX in RA treatment | 24 |
| SP0098 | Joint replacement in OA: friend or foe? | 24 |
| SP0099–SP0102 | Physical activity assessment - what do we know, what do we do, how does it work? | 25 |
| SP0103–SP0104 | How cell death shapes immunity and tolerance | 26 |
| SP0105–SP0107 | “Smoke a joint to protect the joint”. Cannabidiols & neuropeptides in pain and inflammation | 26 |
| SP0108 | EULAR - EMA session | 27 |
| SP0109–SP0110 | Teaching clinical skills | 27 |
| SP0111–SP0113 | Local procedures including aspirations, injections and biopsies I | 27 |
| SP0114–SP0117 | MRI I | 28 |
| SP0118–SP0121 | The Health Professionals' approach to pain management in inflammatory arthritis and osteoarthritis | 29 |
| Friday, 10 June 2016 | | |
| SP0122 | News from kinase inhibitors | 29 |
| SP0123–SP0125 | Crystal arthritis | 30 |
| SP0126 | HOT session 7 | 30 |
| SP0127 | WIN session 6 | 31 |
| SP0128 | Difficult to treat rheumatoid arthritis | 31 |
| SP0129 | Biomarkers: powerful or powderpuff? | 31 |
| SP0130 | HOT session 8 | 31 |
| SP0131–SP0132 | The role of nuclear medicine in rheumatology | 31 |
| SP0133–SP0134 | PROMs/PROs in rheumatological research - time for a critical appraisal? | 32 |
| SP0135–SP0137 | Collaboration for success. User-centred design for improvement of health services | 32 |
| SP0138 | ER stress & rheumatic disease | 33 |
| SP0139–SP0140 | Role of imaging in childhood-onset rheumatic diseases | 33 |
| SP0141 | Physician-patient relationship in the era of interactive media | 34 |
| SP0142 | Capillaroscopy II | 35 |
| SP0143–SP0146 | Ultrasound advanced I | 35 |
| SP0147–SP0148 | It's in your hands | 36 |
| SP0149 | The EULAR School of Rheumatology - a new era of education | 36 |
| SP0150 | Vaccination in rheumatic patients: a two-edged sword | 37 |
| SP0151–SP0153 | Advances in large vessel vasculitis | 37 |
| SP0154 | HOT session 9 | 38 |
| SP0155 | When and how to diagnose and treat vitamin D deficiency? | 38 |
| SP0156 | Data harmonization across (rheumatoid arthritis) clinical cohorts and registers | 38 |
| SP0157–SP0159 | Telemedicine and e-health in community care | 39 |
| SP0160 | Inflammasome as therapeutic target in inflammatory diseases | 39 |
| SP0161 | What's new: latest advances in treatment and management of systemic sclerosis and fibromyalgia | 39 |
| SP0162 | EULAR projects in Investigative Rheumatology | 40 |
| Saturday, 11 June 2016 | | |
| SP0163 | WIN session 8 | 40 |
| SP0164–SP0165 | The elderly patient with osteoarthritis | 40 |
| SP0166–SP0168 | SLE: what will it be and how will it be treated 5 years from now | 40 |
| SP0169 | HOT session 10 | 41 |
| SP0170 | “Time is joint”: early recognition and treatment of arthritis | 41 |
| SP0171–SP0173 | Clinical outcomes for PMR/GCA | 41 |
| SP0174–SP0175 | Getting active against rheumatoid arthritis fatigue | 42 |
| SP0176 | Endothelial to mesenchymal transition and angiogenesis as driving mechanisms in systemic sclerosis | 43 |
| SP0177 | Cell-cell interaction in joint inflammation | 43 |
| SP0178–SP0179 | Transition of care | 43 |
| SP0180–SP0181 | New approaches to understanding and managing chronic musculoskeletal pain | 43 |
| SP0182 | Seronegative inflammatory arthritis: diagnostic and management challenges | 44 |

| | | |
|---------------|---|----|
| SP0183 | HOT session 11 | 44 |
| SP0184–SP0186 | Paget's and other rare bone diseases | 45 |
| SP0187–SP0189 | Analytical issues of complex databases | 45 |
| SP0190–SP0193 | Intimate life and sexual relations in RA | 46 |
| SP0194–SP0195 | Bone and heart: common molecular mechanisms in osteoporosis and atherosclerosis | 47 |
| SP0196 | Adiposity as a driver of arthritis through inflammatory mechanisms | 47 |
| SP0197–SP0200 | EULAR educational offer | 47 |
| SP0201–SP0203 | There is more than drugs | 48 |

Scientific Abstracts

Oral Presentations

Wednesday, 8 June 2016

| | | |
|-------------------------|--|----|
| OP0001–OP0002 | Axial spondyloarthritis and psoriatic arthritis: emerging pathways | 52 |
| OP0003 | Balancing benefits and risk of glucocorticoids; a challenge for implementation | 53 |
| OP0004–OP0005 | What CVD outcomes to use in clinical rheumatological practice? | 54 |
| OP0006–HPR | Different perspectives on pain in osteoarthritis | 55 |
| OP0007–OP0008 | Epigenetics solving the OA puzzle | 55 |
| OP0009–OP0010 | Muscle biology & inflammation | 56 |
| OP0011–OP0012 | Lessons from the children (monogenic causes of autoimmunity) | 56 |
| OP0013 | ABC of statistics | 57 |
| OP0014–PARE | Optimizing treatment and patient care through precision medicine: a threat or an opportunity for patients and patient organisations? | 58 |
| OP0015–OP0016 | Clinical relevance of immunogenicity and therapeutic drug monitoring | 58 |
| OP0017–OP0018 | Outcome measures in clinical practice in gout and CPPD. The use of the new EULAR guidelines | 59 |
| OP0019–HPR | Hand osteoarthritis: state of the art and future perspectives | 60 |
| OP0020–OP0021–HPR | Chronobiology of the immune reponse | 60 |
| OP0022–OP0023 | Nanomedicine in rheumatology | 61 |
| OP0024–PARE–OP0025–PARE | Patient organisations in action | 61 |

Thursday, 9 June 2016

| | | |
|-------------------------|---|-----|
| OP0026–OP0027 | Plasma cells as key players and therapeutic target in rheumatic disaeses | 62 |
| OP0028–OP0029 | Global year against joint pain | 63 |
| OP0030–OP0038 | Diagnosis and management of SSc | 64 |
| OP0039–LB0001 | Advances in SLE therapeutics | 68 |
| OP0159–OP0166 | New pathways to treatment | 116 |
| OP0053–LB0002 | Vasculitis | 74 |
| OP0060–HPR–OP0067–HPR | Developing evidence-based non-pharmacological care | 77 |
| OP0068–OP0075 | Cartilage, bone, synovium | 80 |
| OP0076–OP0083 | SpA and PsA basic and translational research | 83 |
| OP0084–OP0091 | SpA and PsA clinical | 86 |
| OP0092–OP0099 | New horizons in osteoarthritis | 89 |
| OP0100–OP0107 | Clinical osteoporosis: new insights | 92 |
| OP0175–OP0182 | Prognosis and outcome in RA | 122 |
| OP0116–PARE–OP0117–PARE | Designing solutions to support young people to address the challenges of living with a rheumatic or musculoskeletal disease | 99 |
| OP0118–OP0125 | New insights into imaging | 100 |
| OP0126–OP0127 | Advancements in the imaging of PsA | 103 |
| OP0128–OP0129 | When and how to treat Raynaud's phenomenon and related complications | 104 |
| OP0130–OP0131 | Role of new imaging techniques as RMD outcomes | 105 |
| OP0132–HPR | "Fewer words - more action" - tailored care for men with rheumatic diseases? | 106 |
| OP0133–OP0134 | Recent advances in our understanding of macrophage biology | 106 |
| OP0135 | Lubricants: potential as osteoarthritis treatment? | 107 |
| OP0136–OP0137 | Extraarticular complications of JIA | 107 |
| OP0138 | The elephant in the room: how to avoid biases in research? | 108 |
| OP0139–PARE–OP0140–PARE | Digital applications for the benefit of the patient | 108 |

| | | |
|-------------------------------|--|-----|
| OP0141–OP0142 | Optimization of MTX in RA treatment | 109 |
| OP0143–OP0144 | Joint replacement in OA: friend or foe? | 110 |
| OP0145–OP0146 | How to identify and follow patients with inflammatory back pain? | 111 |
| OP0147–HPR | Physical activity assessment - what do we know, what do we do, how does it work? | 112 |
| OP0148 | How cell death shapes immunity and tolerance | 112 |
| OP0149–OP0150 | “Smoke a joint to protect the joint”. Cannabidiols & neuropeptides in pain and inflammation | 112 |
| OP0151 | Teaching clinical skills | 113 |
| OP0152–PARE–OP0153–PARE | What is done for people with rare diseases? Can we do more? | 113 |
| OP0154–HPR | The Health Professionals’ approach to pain management in inflammatory arthritis and osteoarthritis | 114 |
| Friday, 10 June 2016 | | |
| OP0155–OP0156 | News from kinase inhibitors | 114 |
| OP0157–OP0158 | Crystal arthritis | 115 |
| OP0045–OP0052 | Scleroderma, myositis and related conditions | 71 |
| OP0167–OP0174 | Epidemiology of RMDs | 119 |
| OP0108–OP0115 | Expanding therapeutic options in spondyloarthritis | 95 |
| OP0183–OP0190 | SLE, Sjögren’s and APS: clinical aspects (other than treatment) | 126 |
| OP0191–HPR–OP0198–HPR | Shared decision making | 129 |
| OP0199–OP0206 | Novel insights into B and T cell immunity in rheumatic disease | 132 |
| OP0207–OP0214 | An inflammatory update! | 135 |
| OP0215–OP0222 | Advances in paediatric rheumatology | 138 |
| OP0223–OP0230 | Developments in the treatment of RA | 141 |
| OP0231–OP0238 | Emerging concepts in genomics & genetics | 145 |
| OP0239–OP0246 | Novel clues solved in RA development | 148 |
| OP0247–PARE–OP0254–PARE | PARE abstract session | 152 |
| OP0255–OP0262 | Cormobidities | 154 |
| OP0263–OP0264 | Biomarkers: powerful or powderpuff? | 158 |
| OP0265–OP0266 | The role of nuclear medicine in rheumatology | 158 |
| OP0267–HPR–OP0268 | PROMs/PROs in rheumatological research - time for a critical appraisal? | 159 |
| OP0269–HPR | Collaboration for success. User-centred design for improvement of health services | 160 |
| OP0270–OP0271 | ER stress & rheumatic disease | 160 |
| OP0272–OP0273 | Joint EULAR - EFIS session: Do stromal cells house and cure immune cells? | 161 |
| OP0274–OP0275 | Role of imaging in childhood-onset rheumatic diseases | 162 |
| OP0276–OP0277–PARE | Physician-patient relationship in the era of interactive media | 162 |
| OP0278–PARE | It’s in your hands | 163 |
| OP0279 | The EULAR School of Rheumatology - a new era of education | 163 |
| OP0280–OP0281 | Advances in large vessel vasculitis | 164 |
| OP0282–OP0283 | When and how to diagnose and treat vitamin D deficiency? | 165 |
| OP0284–OP0285 | Data harmonization across (rheumatoid arthritis) clinical cohorts and registers | 165 |
| OP0286–HPR | Telemedicine and e-health in community care | 166 |
| OP0287 | Inflammasome as therapeutic target in inflammatory diseases | 166 |
| OP0289–OP0290 | Potential targets in inflammatory fibrotic conditions in SSc | 167 |
| Saturday, 11 June 2016 | | |
| OP0291 | SLE: What will it be and how will it be treated 5 years from now | 168 |
| OP0292–OP0293 | Clinical outcomes for PMR/GCA | 168 |
| OP0294–HPR–OP0295–HPR | Getting active against rheumatoid arthritis fatigue | 169 |
| OP0296–OP0297 | Endothelial to mesenchymal transition and angiogenesis as driving mechanisms in systemic sclerosis. | 170 |
| OP0298–OP0299 | Cell-cell interaction in joint inflammation | 170 |
| OP0300–OP0301 | Transition of care | 171 |
| OP0302–PARE–OP0303–PARE | New approaches to understanding and managing chronic musculoskeletal pain | 172 |
| OP0304–OP0305 | Picking knowledge from other medical disciplines for SSc | 172 |
| OP0306 | Paget’s and other rare bone diseases | 173 |
| OP0307 | Analytical issues of complex databases | 174 |
| OP0308–HPR | Intimate life and sexual relations in RA | 174 |

| | | |
|-------------------------|---|-----|
| OP0309–OP0310 | Bone and heart: common molecular mechanisms in osteoporosis and atherosclerosis ... | 174 |
| OP0311–OP0312 | Adiposity as a driver of arthritis through inflammatory mechanisms | 175 |
| OP0313–PARE–OP0314–PARE | There is more than drugs | 176 |

Late Breaking Abstracts

Thursday, 9 June 2016

| | | |
|--------|------------------------------------|----|
| LB0001 | Advances in SLE therapeutics | 70 |
| LB0002 | Vasculitis | 77 |

Poster Presentations

Thursday, 9 June 2016

Guided Poster Tours

| | | |
|------------------------|--|------|
| T1: THU0001–THU0010 | Immunity in rheumatic diseases | 178 |
| T2: THU0016–THU0023 | Cartilage, bone, synovium | 183 |
| T3: THU0029–THU0036 | Prognosis and outcome in RA | 187 |
| T4: THU0073–THU0082 | Comorbidities update 2016, part 1 | 205 |
| T5: THU0165–THU0173 | RA treatments - non-biological, small molecules | 243 |
| T6: THU0213–THU0222 | Arthritis in childhood | 264 |
| T7: THU0240–THU0251 | Walk through new pathways, biomarkers and potential treatments in SLE and Sjögren's .. | 275 |
| T8: THU0363–THU0372 | SpA and PsA basic an translational research | 318 |
| T9: THU0374–THU0383 | Axial SpA - clinical aspects | 322 |
| T10: THU0418–THU0427 | Psoriatic arthritis | 340 |
| T11: THU0456–THU0465 | How to treat osteoporosis in patients with elevated disease | 357 |
| T12: THU0490–THU0499 | Crystal and metabolic bone diseases; bone diseases other than osteoporosis | 369 |
| T13: THU0541–THU0550 | Clinical aspects of fibromyalgia | 388 |
| T14: THU0593–THU0602 | Outcome measures of RMDs | 406 |
| T15: PARE0001–PARE0008 | PARE Poster tour I | 1320 |

Posters

| | | |
|-----------------|--|-----|
| THU0001–THU0015 | Adaptive immunity (T cells and B cells) in rheumatic diseases | 178 |
| THU0016–THU0028 | Cartilage, synovium and osteoimmunology | 183 |
| THU0029–THU0072 | Rheumatoid arthritis - prognosis, predictors and outcome | 187 |
| THU0073–THU0119 | Rheumatoid arthritis - comorbidity and clinical aspects | 205 |
| THU0120–THU0164 | Rheumatoid arthritis - anti-TNF therapy | 223 |
| THU0165–THU0211 | Rheumatoid arthritis - non-biologic treatment and small molecules | 243 |
| THU0212 | Basic science in paediatric rheumatology | 264 |
| THU0213–THU0239 | Paediatric rheumatology | 264 |
| THU0240–THU0281 | SLE, Sjögren's and APS - etiology, pathogenesis and animal models | 275 |
| THU0282–THU0314 | SLE, Sjögren's and APS - treatment | 289 |
| THU0315–THU0362 | SLE, Sjögren's and APS - clinical aspects (other than treatment) | 301 |
| THU0363–THU0373 | Spondyloarthritis - etiology, pathogenesis and animal models | 318 |
| THU0374–THU0417 | Spondyloarthritis - clinical aspects (other than treatment) | 322 |
| THU0418–THU0455 | Psoriatic arthritis | 340 |
| THU0456–THU0489 | Osteoporosis | 357 |
| THU0490–THU0540 | Crystal diseases, metabolic bone diseases and bone diseases other than osteoporosis .. | 369 |
| THU0541–THU0560 | Fibromyalgia | 388 |
| THU0561–THU0591 | Other orphan diseases | 394 |
| THU0593–THU0638 | Epidemiology, health services and outcome research | 406 |

Friday, 10 June 2016

Guided Poster Tours

| | | |
|---------------------|---|-----|
| F1: FRI0001–FRI0007 | Time for some fun with molecules | 426 |
| F2: FRI0042–FRI0051 | Biology of RA I | 441 |
| F3: FRI0106–FRI0114 | Comorbidities update 2016, part 2 | 466 |
| F4: FRI0154–FRI0163 | RA treatment: predictors, tapering and biosimilars | 484 |
| F5: FRI0198–FRI0207 | Safety and efficacy of non-TNF α blockers in the treatment of RA - I | 502 |

| | | | |
|------|-------------------------|---|------|
| F6: | FRI0238–FRI0246 | From research to biomarkers and targeting SSc | 520 |
| F7: | FRI0248–FRI0257 | Scleroderma, myositis and related syndromes I | 523 |
| F8: | FRI0305–FRI0314 | SLE and APS - clinical aspects | 545 |
| F9: | FRI0354–FRI0362 | Vasculitis I | 563 |
| F10: | FRI0394–FRI0404 | SPA - clinical | 577 |
| F11: | FRI0513–FRI0522 | Imaging in RMD - adding value | 624 |
| F12: | FRI0550–FRI0560 | Epidemiology of RMDs | 639 |
| F13: | FRI0599–FRI0608 | Education | 659 |
| F14: | FRI0643-HPR–FRI0652-HPR | Focus on rehabilitation | 1286 |
| F15: | PARE0009–PARE0017 | PARE Poster tour II | 1322 |

Posters

| | | |
|-----------------|--|-----|
| FRI0001–FRI0041 | Cytokines and inflammatory mediators | 426 |
| FRI0042–FRI0061 | Rheumatoid arthritis - etiology, pathogenesis and animal models | 441 |
| FRI0062–FRI0105 | Rheumatoid arthritis - prognosis, predictors and outcome | 448 |
| FRI0106–FRI0153 | Rheumatoid arthritis - comorbidity and clinical aspects | 466 |
| FRI0154–FRI0197 | Rheumatoid arthritis - anti-TNF therapy | 484 |
| FRI0198–FRI0237 | Rheumatoid arthritis - other biologic treatment | 502 |
| FRI0238–FRI0239 | Scleroderma, myositis and related syndromes | 520 |
| FRI0240–FRI0247 | Scleroderma, myositis and related syndromes - etiology, pathogenesis and animal models | 520 |
| FRI0248–FRI0304 | Scleroderma, myositis and related syndromes | 523 |
| FRI0305–FRI0353 | SLE, Sjögren's and APS - clinical aspects (other than treatment) | 545 |
| FRI0354–FRI0393 | Vasculitis | 563 |
| FRI0394–FRI0438 | Spondyloarthritis - clinical aspects (other than treatment) | 577 |
| FRI0439–FRI0478 | Psoriatic arthritis | 594 |
| FRI0479–FRI0512 | Other orphan diseases | 611 |
| FRI0513–FRI0549 | Diagnostics and imaging procedures | 624 |
| FRI0550–FRI0598 | Epidemiology, health services and outcome research | 639 |
| FRI0599–FRI0609 | Education | 659 |

Saturday, 11 June 2016**Guided Poster Tours**

| | | | |
|------|-------------------------|--|------|
| S1: | SAT0001–SAT0010 | Genetic basis and genomics of disease | 664 |
| S2: | SAT0021–SAT0030 | Innate immune cells coming to play | 671 |
| S3: | SAT0042–SAT0051 | Biology of RA II | 678 |
| S4: | SAT0144–SAT0153 | Safety and efficacy of non-TNF α blockers in the treatment of RA - II | 716 |
| S5: | SAT0184–SAT0194 | Basic research in systemic sclerosis | 735 |
| S6: | SAT0195–SAT0204 | Scleroderma, myositis and related syndromes II | 738 |
| S7: | SAT0253–SAT0262 | Juvenile-onset connective tissue diseases | 760 |
| S8: | SAT0281–SAT0290 | SLE and Sjögren's: clinical aspects | 769 |
| S9: | SAT0330–SAT0338 | Vasculitis II | 786 |
| S10: | SAT0371–SAT0380 | Optimising treatment of axial SpA | 801 |
| S11: | SAT0424–SAT0433 | New insights in osteoarthritis | 824 |
| S12: | SAT0481–SAT0490 | Infection related rheumatic diseases | 844 |
| S13: | SAT0502–SAT0511 | New approaches to back pain - soft tissue problems | 851 |
| S14: | SAT0528–SAT0537 | Imaging RMD: what else? | 860 |
| S15: | SAT0637-HPR–SAT0644-HPR | Getting around rheumatic disease | 1294 |

Posters

| | | |
|-----------------|--|-----|
| SAT0001–SAT0020 | Genomics, genetic basis of disease and HLA/T cell recognition | 664 |
| SAT0021–SAT0030 | Innate immunity in rheumatic diseases | 671 |
| SAT0031–SAT0051 | Rheumatoid arthritis - etiology, pathogenesis and animal models | 675 |
| SAT0052–SAT0095 | Rheumatoid arthritis - prognosis, predictors and outcome | 682 |
| SAT0096–SAT0143 | Rheumatoid arthritis - comorbidity and clinical aspects | 700 |
| SAT0144–SAT0183 | Rheumatoid arthritis - other biologic treatment | 716 |
| SAT0184–SAT0194 | Scleroderma, myositis and related syndromes - etiology, pathogenesis and animal models | 735 |
| SAT0195–SAT0252 | Scleroderma, myositis and related syndromes | 738 |

| | | |
|-----------------|---|-----|
| SAT0253–SAT0280 | Paediatric rheumatology | 760 |
| SAT0281–SAT0329 | SLE, Sjögren's and APS - clinical aspects (other than treatment) | 769 |
| SAT0330–SAT0370 | Vasculitis | 786 |
| SAT0371–SAT0423 | Spondyloarthritis - treatment | 801 |
| SAT0424–SAT0480 | Osteoarthritis | 824 |
| SAT0481–SAT0501 | Infection-related rheumatic diseases | 844 |
| SAT0502–SAT0527 | Back pain, mechanical musculoskeletal problems, local soft tissue disorders | 851 |
| SAT0528–SAT0566 | Diagnostics and imaging procedures | 860 |
| SAT0567–SAT0614 | Epidemiology, health services and outcome research | 874 |
| SAT0615–SAT0626 | Rehabilitation | 892 |

Abstracts Accepted for Publication

| | | |
|---------------|--|------|
| AB0001–AB0012 | Genomics, genetic basis of disease and HLA/T cell recognition | 897 |
| AB0013–AB0026 | Adaptive immunity (T cells and B cells) in rheumatic diseases | 901 |
| AB0027–AB0028 | Innate immunity in rheumatic diseases | 906 |
| AB0029–AB0058 | Cytokines and inflammatory mediators | 906 |
| AB0059–AB0078 | Cartilage, synovium and osteoimmunology | 917 |
| AB0079–AB0114 | Rheumatoid arthritis - etiology, pathogenesis and animal models | 923 |
| AB0115–AB0124 | Spondyloarthritis - etiology, pathogenesis and animal models | 936 |
| AB0125–AB0160 | SLE, Sjögren's and APS - etiology, pathogenesis and animal models | 939 |
| AB0161–AB0164 | Scleroderma, myositis and related syndromes - etiology, pathogenesis and animal models | 951 |
| AB0165–AB0166 | Basic science in paediatric rheumatology | 952 |
| AB0167–AB0258 | Rheumatoid arthritis - prognosis, predictors and outcome | 953 |
| AB0259–AB0296 | Rheumatoid arthritis - comorbidity and clinical aspects | 988 |
| AB0297–AB0337 | Rheumatoid arthritis - anti-TNF therapy | 1001 |
| AB0338–AB0381 | Rheumatoid arthritis - other biologic treatment | 1017 |
| AB0382–AB0405 | Rheumatoid arthritis - non-biologic treatment and small molecules | 1035 |
| AB0406–AB0426 | SLE, Sjögren's and APS - treatment | 1045 |
| AB0427–AB0525 | SLE, Sjögren's and APS - clinical aspects (other than treatment) | 1053 |
| AB0526–AB0581 | Vasculitis | 1084 |
| AB0582–AB0653 | Scleroderma, myositis and related syndromes | 1103 |
| AB0654–AB0664 | Spondyloarthritis - treatment | 1128 |
| AB0665–AB0721 | Spondyloarthritis - clinical aspects (other than treatment) | 1132 |
| AB0722–AB0749 | Psoriatic arthritis | 1151 |
| AB0750–AB0767 | Osteoarthritis | 1161 |
| AB0768–AB0798 | Osteoporosis | 1167 |
| AB0799–AB0834 | Crystal diseases, metabolic bone diseases and bone diseases other than osteoporosis | 1177 |
| AB0835–AB0836 | Infection-related rheumatic diseases | 1188 |
| AB0837–AB0842 | Fibromyalgia | 1189 |
| AB0843–AB0854 | Back pain, mechanical musculoskeletal problems, local soft tissue disorders | 1191 |
| AB0855–AB0891 | Paediatric rheumatology | 1194 |
| AB0892–AB0929 | Other orphan diseases | 1207 |
| AB0930–AB0982 | Diagnostics and imaging procedures | 1219 |
| AB0983–AB1056 | Epidemiology, health services and outcome research | 1237 |
| AB1057–AB1062 | Rehabilitation | 1263 |
| AB1063–AB1073 | Education | 1265 |

Health Professionals in Rheumatology Abstracts

Oral Presentations

Wednesday, 8 June 2016

| | | |
|------------|---|----|
| OP0006-HPR | Different perspectives on pain in osteoarthritis | 55 |
| OP0019-HPR | Hand osteoarthritis: State of the art and future perspectives | 60 |
| OP0021-HPR | Chronobiology of the immune reponse | 60 |

Thursday, 9 June 2016

| | | |
|-----------------------|--|-----|
| OP0060-HPR–OP0067-HPR | Developing evidence-based non-pharmacological care | 77 |
| OP0132-HPR | “Fewer words - more action” - tailored care for men with rheumatic diseases? | 106 |
| OP0147-HPR | Physical activity assessment - what do we know, what do we do, how does it work? | 112 |
| OP0154-HPR | The Health Professionals’ approach to pain management in inflammatory arthritis and osteoarthritis | 114 |

Friday, 10 June 2016

| | | |
|-----------------------|---|-----|
| OP0191-HPR–OP0198-HPR | Shared decision making | 129 |
| OP0267-HPR | PROMs/PROs in rheumatological research - time for a critical appraisal? | 159 |
| OP0269-HPR | Collaboration for success. User-centred design for improvement of health services | 160 |
| OP0286-HPR | Telemedicine and e-health in community care | 166 |

Saturday, 9 June 2016

| | | |
|-----------------------|---|-----|
| OP0294-HPR–OP0295-HPR | Getting active against rheumatoid arthritis fatigue | 169 |
| OP0308-HPR | Intimate life and sexual relations in RA | 174 |

Poster Presentations**Thursday, 9 June 2016****Posters**

| | | |
|-------------------------|--|------|
| THU0639-HPR–THU0651-HPR | Miscellaneous forms of clinical care | 1270 |
|-------------------------|--|------|

Friday, 10 June 2016**Guided Poster Tours**

| | | |
|------------------------------|-------------------------------|------|
| F14: FRI0643-HPR–FRI0652-HPR | Focus on rehabilitation | 1286 |
|------------------------------|-------------------------------|------|

Posters

| | | |
|-------------------------|--|------|
| FRI0610-HPR–FRI0652-HPR | Physiotherapy & miscellaneous forms of clinical care | 1275 |
|-------------------------|--|------|

Saturday, 11 June 2016**Guided Poster Tours**

| | | |
|------------------------------|--|------|
| S15: SAT0637-HPR–SAT0644-HPR | Getting around rheumatic disease | 1294 |
|------------------------------|--|------|

Posters

| | | |
|-------------------------|--|------|
| SAT0627-HPR–SAT0636-HPR | Nursing | 1290 |
| SAT0637-HPR | Miscellaneous forms of clinical care | 1294 |
| SAT0638-HPR | Psychology/Social sciences | 1294 |
| SAT0639-HPR | Nursing | 1294 |
| SAT0640-HPR | Miscellaneous forms of clinical care | 1295 |
| SAT0641-HPR | Nursing | 1295 |
| SAT0642-HPR | Psychology/Social sciences | 1295 |
| SAT0643-HPR | Miscellaneous forms of clinical care | 1296 |
| SAT0644-HPR | Nursing | 1296 |
| SAT0645-HPR–SAT0648-HPR | Psychology/Social sciences | 1297 |
| SAT0649-HPR | Occupational therapy | 1298 |

Abstracts Accepted for Publication

| | | |
|-----------------------|--|------|
| AB1074-HPR–AB1085-HPR | Nursing | 1299 |
| AB1086-HPR–AB1092-HPR | Psychology / Social sciences | 1303 |
| AB1093-HPR–AB1110-HPR | Physiotherapy | 1305 |
| AB1111-HPR–AB1113-HPR | Occupational therapy | 1311 |
| AB1114-HPR–AB1130-HPR | Miscellaneous forms of clinical care | 1312 |

People with Arthritis and Rheumatism in Europe Abstracts

Oral Presentations

Wednesday, 8 June 2016

| | | |
|-------------------------|--|----|
| OP0014-PARE | Optimizing treatment and patient care through precision medicine: A threat or an opportunity for patients and patient organisations? | 58 |
| OP0024-PARE–OP0025-PARE | Patient organisations in action | 61 |

Thursday, 9 June 2016

| | | |
|-------------------------|---|-----|
| OP0116-PARE–OP0117-PARE | Designing solutions to support young people to address the challenges of living with a rheumatic or musculoskeletal disease | 99 |
| OP0139-PARE–OP0140-PARE | Digital applications for the benefit of the patient | 108 |
| OP0152-PARE–OP0153-PARE | What is done for people with rare diseases? Can we do more? | 113 |

Friday, 10 June 2016

| | | |
|-------------------------|--|-----|
| OP0247-PARE–OP0254-PARE | PARE abstract session | 152 |
| OP0277-PARE | Physician-patient relationship in the era of interactive media | 163 |
| OP0278-PARE | It's in your hands | 163 |

Saturday, 11 June 2016

| | | |
|-------------------------|---|-----|
| OP0302-PARE–OP0303-PARE | New approaches to understanding and managing chronic musculoskeletal pain | 172 |
| OP0313-PARE–OP0314-PARE | There is more than drugs | 176 |

Poster Presentations

Thursday, 9 June 2016

Guided Poster Tours

| | | |
|------------------------|--------------------------|------|
| T15: PARE0001–PARE0008 | PARE Poster tour I | 1320 |
|------------------------|--------------------------|------|

Friday, 10 June 2016

Guided Poster Tours

| | | |
|------------------------|---------------------------|------|
| F15: PARE0009–PARE0017 | PARE Poster tour II | 1322 |
|------------------------|---------------------------|------|

Thursday, 9 June to Saturday, 11 June 2016

Posters

| | | |
|-------------------|--|------|
| PARE0001–PARE0004 | Patient information and education | 1320 |
| PARE0005–PARE0006 | Building patient led organisations | 1321 |
| PARE0007 | Best practice campaigning | 1322 |
| PARE0008 | Building patient led organisations | 1322 |
| PARE0009 | Best practice campaigning | 1322 |
| PARE0010–PARE0011 | Patient information and education | 1323 |
| PARE0012 | Best practice campaigning | 1324 |
| PARE0013 | Patient information and education | 1324 |
| PARE0014 | Best practice campaigning | 1324 |
| PARE0015 | Innovations in arthritis health care | 1325 |
| PARE0016 | Arthritis research | 1325 |
| PARE0017 | Patient information and education | 1325 |

| | |
|---------------------------|------|
| Author Index | 1327 |
|---------------------------|------|